169 related articles for article (PubMed ID: 31515461)
1. Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma.
Thakur R; Laye JP; Lauss M; Diaz JMS; O'Shea SJ; Poźniak J; Filia A; Harland M; Gascoyne J; Randerson-Moor JA; Chan M; Mell T; Jönsson G; Bishop DT; Newton-Bishop J; Barrett JH; Nsengimana J
Clin Cancer Res; 2019 Dec; 25(24):7424-7435. PubMed ID: 31515461
[TBL] [Abstract][Full Text] [Related]
2. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
3. A nine-gene signature predicting clinical outcome in cutaneous melanoma.
Brunner G; Reitz M; Heinecke A; Lippold A; Berking C; Suter L; Atzpodien J
J Cancer Res Clin Oncol; 2013 Feb; 139(2):249-58. PubMed ID: 23052696
[TBL] [Abstract][Full Text] [Related]
4. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
5. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
[TBL] [Abstract][Full Text] [Related]
6. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
[TBL] [Abstract][Full Text] [Related]
7. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
8. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort.
Nsengimana J; Laye J; Filia A; Walker C; Jewell R; Van den Oord JJ; Wolter P; Patel P; Sucker A; Schadendorf D; Jönsson GB; Bishop DT; Newton-Bishop J
Oncotarget; 2015 May; 6(13):11683-93. PubMed ID: 25871393
[TBL] [Abstract][Full Text] [Related]
9. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
10. A time course-dependent metastatic gene expression signature predicts outcome in human metastatic melanomas.
Chen R; Zhang G; Zhou Y; Li N; Lin J
Diagn Pathol; 2014 Aug; 9():155. PubMed ID: 25116415
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
12. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
Song LB; Luan JC; Zhang QJ; Chen L; Wang HY; Cao XC; Song NH; Lu Y
J Immunol Res; 2021; 2021():6686284. PubMed ID: 33688507
[TBL] [Abstract][Full Text] [Related]
13. Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients.
Hao H; Xiao D; Pan J; Qu J; Egger M; Waigel S; Sanders MA; Zacharias W; Rai SN; McMasters KM
Ann Surg Oncol; 2017 Jan; 24(1):108-116. PubMed ID: 27663566
[TBL] [Abstract][Full Text] [Related]
14. Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.
Yang RK; Kuznetsov IB; Ranheim EA; Wei JS; Sindiri S; Gryder BE; Gangalapudi V; Song YK; Patel V; Hank JA; Zuleger C; Erbe AK; Morris ZS; Quale R; Kim K; Albertini MR; Khan J; Sondel PM
Clin Cancer Res; 2020 Jul; 26(13):3296-3306. PubMed ID: 32152202
[TBL] [Abstract][Full Text] [Related]
15. A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma.
Guo W; Zhu L; Zhu R; Chen Q; Wang Q; Chen JQ
Elife; 2019 Jun; 8():. PubMed ID: 31169496
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
17. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
Gerami P; Cook RW; Wilkinson J; Russell MC; Dhillon N; Amaria RN; Gonzalez R; Lyle S; Johnson CE; Oelschlager KM; Jackson GL; Greisinger AJ; Maetzold D; Delman KA; Lawson DH; Stone JF
Clin Cancer Res; 2015 Jan; 21(1):175-83. PubMed ID: 25564571
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
19. Melanoma sentinel node biopsy and prediction models for relapse and overall survival.
Mitra A; Conway C; Walker C; Cook M; Powell B; Lobo S; Chan M; Kissin M; Layer G; Smallwood J; Ottensmeier C; Stanley P; Peach H; Chong H; Elliott F; Iles MM; Nsengimana J; Barrett JH; Bishop DT; Newton-Bishop JA
Br J Cancer; 2010 Oct; 103(8):1229-36. PubMed ID: 20859289
[TBL] [Abstract][Full Text] [Related]
20. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]